APOE and Alzheimer disease: These results may support earlier reports of altered WM microstructure, e.g., reduced FA14, 15 and increased MD as well as RD13, 14, in ε4 carriers relative to non-carriers, and supports that APOE ε4 is associated with characteristic AD-like biomarker profiles also in healthy and sub-clinical populations12.